Hemostatic tests in the prediction of atherothrombotic disease

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 2, 1997, Pages 145-152

  Wu, Kenneth K ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

C reactive protein; Coronary heart disease; Factor VIIc; Fibrinogen; Hemostatic tests; Ischemic stroke; Myocardial infarction; Plasminogen activator inhibitor 1; Platelet activation; Tissue type plasminogen activator; von Willebrand factor

Indexed keywords

ANGINA;

EID: 0030768531     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02912450     Document Type: Review

References (36)

1. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC Hemotasis Study. I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989; 61:15.
2. Wu KK, Papp AC, Patsch W, Rock R, Eckfeldt J, Sharrett R. ARIC Hemostasis Study. II. Organizational plan and feasibility study. Thromb Haemost 1990; 64:521.
3. Chambless LE, McMahon R, Finch A, Sorlie P, Heiss G, Lyles R, Wu KK. ARIC Hemostasis Study. III. Quality control. Thromb Haemost 1993; 70:588.
4. Nguyen ND, Cheddar H, Stinson V, Chambless LE, Wu KK. ARIC Hemostasis Study. IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995; 73:256.
5. Meads TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG. Hemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1:1050.
6. Meads TW, Mellows S, Brozovic M, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; II:533.
7. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501.
8. Kannel WR, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease, the Framingham Study. JAMA 1987; 258:1183.
9. Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83:836.
10. Heinrich J, Balleisen L, Schultz H, Assmann G, Loo J van de. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study m healthy men. Arterioscler Thromb 1994; 14:54.
11. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. A prospective study of hemostatic factor and incidence of coronary heart disease. The ARIC study. Circulation. In press.
12. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, Vande Loo J, Kinast J, Wu KK, Morrisey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasma deleted of protein C raise the sensitivity of factor VII bioassay to activated factor VII: an international study. Thromb Haemost 1994; 74:38.
13. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338:850.
14. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 1165.
15. Thomson SG, Kienast J, Pyke SDM, Haverkate F, Loo JCW van de. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635.
16. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66:351.
17. Liuzzo G, Biasucci LM, Gallimore R, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417.
18. Hamsten A, Wiman B, Faire Ude, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557.
19. Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman. Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction. Lancet 1987; II:3.
20. Trip MD, Cats VM, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322:1549.
21. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions Aα312 and Bβ448. Blood 1993; 82:2117.
22. Thomas AE, Green FR, Kelleher CH, Wilkes PJ, Meade TW, Humphries SE. Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65:487.
23. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Circulation 1996; 93:440.
24. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11:540.
25. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation m plasma. Arterioscler Thromb Vasc Bol 1996; 16:72.
26. Dawson S, Hamsten A, Wiman B, Henny A, Humphries SE. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of PAI-1 activity. Atherioscler Thromb 1991; 11:183.
27. Eriksson P, Kallin B, Van't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the PAI-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851.
28. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A. Luc G, Cambou JP, Arveiller D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74:837.
29. Weiss E, Bray PF, Tayback M, Schulmann SP, Kickler TS, Becker LC, Weiss JL, Gerstenblich G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334:1090.
30. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic risk factor of venous thromboembolism. Blood 1995; 85:607.
31. Bertina RM, Koeleman BPC, Koster T, Rosendaahl FR, Dirven RJ, deRonde H, Velden PA vander, Ritrsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64.
32. Ridker PM, Henne Kens CH, Lindpaintner K, Stampfer M, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of my ocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912.
33. Malinow MR. Hyperhomocyst(e) inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81:2004.
34. Folsom AR, Wu KK, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen, factor VII putative cardiovascular risk factors. Atherosclerosis 1991; 91:191.
35. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. Thromb Haemost 1993; 70:380.
36. Folsom AR, Damhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor-1 factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13:162.